title: [Cannabinoid mouth spray brought help to a severely spastic young man].
abstract: Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in Finland. Spasticity is one of the main symptoms in cerebral palsies and a risk factor of multiple painful anomalies of the skeletal network. We describe a 28-year-old man with severe cerebral palsy, whose quality of life improved and the need for help decreased by using two daily mouth sprays of cannabinoid.
authors.forename: Maria
authors.initials: M
authors.lastname: Arvio
authors.forename: Nina
authors.initials: N
authors.lastname: Bjelogrlic-Laakso
authors.forename: Tommi
authors.initials: T
authors.lastname: Salokivi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002186:Cannabinoids / Q000008:administration & dosage*; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000503:physiopathology; D005387:Finland; D006801:Humans; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy / Q000503:physiopathology; D011788:Quality of Life
chemical_list: D002186:Cannabinoids